TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Issue 8 (25th May 2021) - Morabito, Fortunato; Del Poeta, Giovanni; Mauro, Francesca Romana; Reda, Gianluigi; Sportoletti, Paolo; Laurenti, Luca; Coscia, Marta; Herishanu, Yair; Bossio, Sabrina; Varettoni, Marzia; Murru, Roberta; Chiarenza, Annalisa; et al.